All lobbying filings

DLA PIPER LLP (US)

Lobbying for NOVARTIS · Innovative medicines company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 3

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 5

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Taxation/Internal Revenue Code

Tax reform and tax policy.

Trade (domestic/foreign)

Tariffs.

Health Issues

Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy.

Medicare/Medicaid

Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.